UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 3, 2005
Abgenix, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-24207 | | 94-3248826 |
(Commission File Number) | | (IRS Employer Identification No.) |
6701 Kaiser Drive, Fremont California | | 94555 |
(Address of Principal Executive Offices) | | (Zip Code) |
510-284-6500
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On November 3, 2005, Abgenix, Inc. and Amgen Inc. issued a press release announcing that a pivotal Phase 3 study of panitumumab met the primary endpoint of improving progression-free survival in patients with metastatic colorectal cancer who had failed standard chemotherapy.
A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated herein.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
Exhibit
No. | | Description |
| | |
99.1 | | Press Release dated November 3, 2005 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABGENIX, INC. |
| | |
Dated: November 3, 2005 | By: | /s/ H. Ward Wolff |
| | H. Ward Wolff |
| | Chief Financial Officer and |
| | Senior Vice President, Finance |
3
EXHIBIT INDEX
EXHIBIT
NO. | | DESCRIPTION |
| | |
99.1 | | Press Release dated Novmber 3, 2005 |
4
